What's in Aurobindo Pharma Ltd's pipeline?

Aurobindo Pharma Ltd has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Aurobindo Pharma Ltd's portfolio?

Top competitors by shared drug class: Astellas Pharma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/aurobindo-pharma-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Aurobindo Pharma Ltd — Portfolio Competitive Intelligence Brief

Aurobindo Pharma Ltd pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Amphotericin B Liposome	Amphotericin B Liposome	marketed	Lipid-based Polyene Antifungal [EPC]

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Astellas Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Aurobindo Pharma Ltd:

Cite this brief

Drug Landscape (2026). Aurobindo Pharma Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aurobindo-pharma-ltd. Accessed 2026-05-14.